These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9080540)

  • 1. Plasma tryptophan levels and tryptophan/neutral amino acid ratios in obsessive-compulsive patients with and without depression.
    Bellodi L; Erzegovesi S; Bianchi L; Lucini V; Conca R; Lucca A
    Psychiatry Res; 1997 Mar; 69(1):9-15. PubMed ID: 9080540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma tryptophan levels and plasma tryptophan/neutral amino acids ratio in patients with mood disorder, patients with obsessive-compulsive disorder, and normal subjects.
    Lucca A; Lucini V; Piatti E; Ronchi P; Smeraldi E
    Psychiatry Res; 1992 Nov; 44(2):85-91. PubMed ID: 1480681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression.
    Maina G; Rosso G; Rigardetto S; Chiadò Piat S; Bogetto F
    Psychother Psychosom; 2010; 79(5):295-302. PubMed ID: 20616624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
    Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
    J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
    den Boer JA
    J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of depression on the treatment of obsessive-compulsive disorder: results from a 5-year follow-up.
    Anholt GE; Aderka IM; van Balkom AJ; Smit JH; Hermesh H; de Haan E; van Oppen P
    J Affect Disord; 2011 Dec; 135(1-3):201-7. PubMed ID: 21889802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment.
    Monteleone P; Catapano F; Di Martino S; Ferraro C; Maj M
    Br J Psychiatry; 1997 Jun; 170():554-7. PubMed ID: 9330023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor.
    Lucca A; Lucini V; Catalano M; Alfano M; Smeraldi E
    Neuropsychobiology; 1994; 29(3):108-11. PubMed ID: 8022529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment.
    Monteleone P; Catapano F; Bortolotti F; Maj M
    Biol Psychiatry; 1997 Aug; 42(3):175-80. PubMed ID: 9232209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
    Marazziti D; Pfanner C; Palego L; Gemignani A; Milanfranchi A; Ravagli S; Lensi P; Presta S; Cassano GB
    Pharmacopsychiatry; 1997 Nov; 30(6):245-9. PubMed ID: 9442546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors.
    Lucini V; Lucca A; Catalano M; Smeraldi E
    Adv Exp Med Biol; 1996; 398():559. PubMed ID: 8906324
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
    Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
    Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma ratio tryptophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression.
    Møller SE; Bech P; Bjerrum H; Bøjholm S; Butler B; Folker H; Gram LF; Larsen JK; Lauritzen L; Loldrup D
    J Affect Disord; 1990 Jan; 18(1):59-66. PubMed ID: 2136870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.